Infliximab 5–10 mg/kg may leads to higher clinical response defined as improvement in the scores on the CDAI… compared with placebo (low certainty).
It is very uncertain whether infliximab 5 mg/kg changes clinical response as defined by the studies week 4 compared with infliximab 20 mg/kg (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether infliximab 10 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 20 mg/kg (very low certainty).
It is very uncertain whether infliximab 10 mg/kg changes clinical response defined by reduction of CDAI score by ≥ 70 at week 4 compared with infliximab 20 mg/kg (very low certainty).
The review found no eligible studies for this question.
Infliximab 5 mg/kg showed no clear difference in clinical remission defined as CDAI < 150 at week 6 compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
Infliximab 5 mg/kg showed no clear difference in clinical response defined by reduction of CDAI score by ≥ 100 at… compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether infliximab 5–10 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with placebo (very low certainty).
It is very uncertain whether infliximab 5–10 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with placebo (very low certainty).
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical remission as defined by the studies at weeks 24–26 compared with purine analogues alone (moderate certainty).
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
Vedolizumab leads to higher induction of clinical remission (6–10 weeks) compared with placebo (high certainty).
Vedolizumab leads to higher induction of clinical response (6–10 weeks) compared with placebo (high certainty).
Vedolizumab showed no clear difference in adverse events (6–10 weeks) compared with placebo (moderate certainty).
Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).
Vedolizumab leads to higher maintenance of clinical remission (52–60 weeks) compared with placebo (high certainty).